PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1882973
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1882973
Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of measles, mumps, rubella (MMR) vaccines Market
The global measles, mumps, rubella (MMR) vaccines market is expanding rapidly due to rising infectious disease prevalence, increasing global immunization efforts, and strong support from major health organizations. According to the report, the market size was USD 5.06 billion in 2024, is expected to increase to USD 5.17 billion in 2025, and reach USD 11.01 billion by 2032, exhibiting a CAGR of 11.4% during the forecast period. In 2024, North America held the largest share at 37.15%, driven by robust public health systems and high vaccination coverage.
MMR vaccines protect against three highly contagious viral diseases-measles, mumps, and rubella-using weakened live viruses to induce immunity. Administered in two doses, typically at 12 months and again at 4 years of age, these vaccines demonstrate strong effectiveness. CDC data published in January 2025 shows the first MMR dose is 93% effective against measles, 72% effective against mumps, and 97% effective against rubella, supporting their continued global adoption. Increasing R&D activities by vaccine manufacturers such as GSK plc., Serum Institute of India Pvt. Ltd., and Merck & Co., Inc. further accelerate market progress.
Market Dynamics
Drivers
Government-backed immunization programs are a major driver of global MMR vaccine demand. Countries such as the U.S. and India have integrated MMR into national immunization schedules, ensuring widespread availability for eligible children. Global organizations, including WHO and Gavi, amplify these efforts through financial and logistical support. For example, in May 2025, Gavi reported supporting measles-rubella catch-up campaigns in multiple countries before MR vaccines were added to routine immunization.
Restraints
Vaccine hesitancy remains one of the most significant barriers to market growth. Factors such as misinformation, misconceptions about side effects, and distrust in healthcare systems reduce vaccine acceptance. According to an October 2023 publication by the National Center for Biotechnology Information, many parents avoided MMR vaccination due to concerns about fever and injection-site pain, demonstrating the influence of perceived risks on uptake.
Opportunities
Technological advancements such as microarray patches (MAPs) create significant opportunities for needle-free, thermostable, and easy-to-administer MMR vaccines. These innovations improve compliance, especially in low-income regions with limited healthcare access. UNICEF and WHO began developing microarray patches in collaboration with partners in 2019, offering a strong pathway for future adoption.
Challenges
Maintaining cold chain integrity presents an ongoing challenge. MMR vaccines are extremely sensitive to temperature fluctuations, and improper handling can reduce efficacy and increase wastage. A September 2024 CDC Foundation report confirmed the measles vaccine's high vulnerability to temperature variations, highlighting cold-chain limitations in many regions.
Market Trends
A key trend shaping the MMR vaccine market is the rise in public-private partnerships aimed at addressing immunization gaps. These collaborations enhance distribution, improve vaccine logistics, and strengthen community engagement. Gavi data published in May 2025 showed that USD 55 million was allocated to the Measles & Rubella Initiative between 2013 and 2017, demonstrating long-term financial commitment to disease control.
Segmentation Insights
By Type
The combination vaccine segment dominated in 2024 due to its convenience, cost-effectiveness, and ability to protect against all three diseases through a single injection. FDA approval of GSK's Priorix in June 2022 further strengthened segment growth.
By Product
M-M-R II led the market in 2024, supported by more than 231 million doses sold in the U.S. over 30 years, indicating long-proven global usage. PRIORIX is expected to grow rapidly due to its wide regulatory approvals and strong clinical evidence.
By Route of Administration
The subcutaneous route accounted for the largest share in 2024, as most MMR vaccines-including M-M-R II and PRIORIX-are approved for SC administration.
By Age Group
The pediatric segment held the highest share in 2024 due to heightened susceptibility of children and strong inclusion of MMR in childhood immunization schedules.
By Distribution Channel
Government suppliers dominated due to large-scale procurement for national immunization programs. UNICEF procured 181 million MR vaccine doses in 2021 on behalf of 35 countries.
Regional Outlook
In 2024, North America generated USD 1.88 billion, driven by strong vaccination infrastructure and public health initiatives. The U.S. leads the region with comprehensive immunization policies and continuous disease monitoring. Europe holds a strong share due to mandatory two-dose schedules across EU/EEA countries. Asia Pacific is the fastest-growing region due to expansions of national immunization programs and free vaccine administration under initiatives such as India's Universal Immunization Programme (UIP). Latin America and Middle East & Africa show steady growth supported by rising awareness and improving healthcare access.
Conclusion
Expanding from USD 5.06 billion in 2024 to USD 11.01 billion by 2032, the MMR vaccines market is set for strong growth through improved awareness, technological innovation, public-private collaborations, and strengthened immunization programs worldwide.
Segmentation By Type
- Standalone
- Combination
By Product
- M-M-R II
- PRIORIX
- M-M-RvaxPro
- Tresivac
- Others
By Route of Administration
- Intramuscular
- Subcutaneous
- Others
By Age Group
- Adult
- Pediatric
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Overview: Immunization Coverage, By Key Countries
- 4.4. Technological Advancements in the MMR Vaccines
- 4.5. New Product Launches, By Key Players
- 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Standalone
- 5.1.2. Combination
- 5.2. Market Analysis, Insights and Forecast - By Product
- 5.2.1. M-M-R II
- 5.2.2. PRIORIX
- 5.2.3. M-M-RvaxPro
- 5.2.4. Tresivac
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Intramuscular
- 5.3.2. Subcutaneous
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Age Group
- 5.4.1. Pediatrics
- 5.4.2. Adults
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital & Retail Pharmacies
- 5.5.2. Government Suppliers
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Standalone
- 6.1.2. Combination
- 6.2. Market Analysis, Insights and Forecast - By Product
- 6.2.1. M-M-R II
- 6.2.2. PRIORIX
- 6.2.3. M-M-RvaxPro
- 6.2.4. Tresivac
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Intramuscular
- 6.3.2. Subcutaneous
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Age Group
- 6.4.1. Pediatrics
- 6.4.2. Adults
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital & Retail Pharmacies
- 6.5.2. Government Suppliers
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Standalone
- 7.1.2. Combination
- 7.2. Market Analysis, Insights and Forecast - By Product
- 7.2.1. M-M-R II
- 7.2.2. PRIORIX
- 7.2.3. M-M-RvaxPro
- 7.2.4. Tresivac
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Intramuscular
- 7.3.2. Subcutaneous
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Age Group
- 7.4.1. Pediatrics
- 7.4.2. Adults
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital & Retail Pharmacies
- 7.5.2. Government Suppliers
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Standalone
- 8.1.2. Combination
- 8.2. Market Analysis, Insights and Forecast - By Product
- 8.2.1. M-M-R II
- 8.2.2. PRIORIX
- 8.2.3. M-M-RvaxPro
- 8.2.4. Tresivac
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Intramuscular
- 8.3.2. Subcutaneous
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Age Group
- 8.4.1. Pediatrics
- 8.4.2. Adults
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital & Retail Pharmacies
- 8.5.2. Government Suppliers
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Standalone
- 9.1.2. Combination
- 9.2. Market Analysis, Insights and Forecast - By Product
- 9.2.1. M-M-R II
- 9.2.2. PRIORIX
- 9.2.3. M-M-RvaxPro
- 9.2.4. Tresivac
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Intramuscular
- 9.3.2. Subcutaneous
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Age Group
- 9.4.1. Pediatrics
- 9.4.2. Adults
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital & Retail Pharmacies
- 9.5.2. Government Suppliers
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Standalone
- 10.1.2. Combination
- 10.2. Market Analysis, Insights and Forecast - By Product
- 10.2.1. M-M-R II
- 10.2.2. PRIORIX
- 10.2.3. M-M-RvaxPro
- 10.2.4. Tresivac
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Intramuscular
- 10.3.2. Subcutaneous
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Age Group
- 10.4.1. Pediatrics
- 10.4.2. Adults
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital & Retail Pharmacies
- 10.5.2. Government Suppliers
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. GSK plc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Serum Institute of India Pvt. Ltd.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Indian Immunologicals Limited
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Zydus Lifesciences Limited
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Takeda Pharmaceutical Company Limited
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. BIOLOGICAL E. LIMITED
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Invivyd, Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Daiichi Sankyo Company, Limited
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. GSK plc.
List of Tables
- Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
- Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024 & 2032
- Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
- Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024 & 2032
- Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024 & 2032
- Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2024 & 2032
- Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
- Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
- Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
- Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
- Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2024 & 2032
- Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2024
- Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
- Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
- Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
- Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
- Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
- Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
- Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
- Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
- Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
- Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
- Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
- Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
- Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
- Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
- Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
- Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
- Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
- Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2024
